Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q1 EPS of ($0.95), $0.03 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $13 million versus the consensus estimate of $11.92 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.